Krystal Biotech (KRYS) Operating Margin (2023 - 2026)

Krystal Biotech has reported Operating Margin for 4 years, with the latest figure at 49.0% in Q2 2026.

• Operating Margin for Q2 2026 came in at 49.0%, up 798.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 44.89% (up 605.0% YoY), and the FY2025 annual result was 41.45%, up 1882.0% from the prior year.
• Operating Margin grew to 49.0% in Q2 2026, from 46.12% in the prior quarter.
• Over five years, Operating Margin peaked at 49.0% in Q2 2026 and troughed at 303.8% in Q3 2023.
• A 4-year average of 2.87% and a median of 41.06% in 2025 frame the typical range for Operating Margin.
• The widest annual swing landed in 2024, when Operating Margin surged 33060 bps; it then sank 408 bps in 2025.
• A 4-year view of Operating Margin shows it stood at 7.71% in 2023, then jumped by 489 bps to 45.41% in 2024, then retreated by 9 bps to 41.33% in 2025, then advanced by 19 bps to 49.0% in 2026.
• Per Business Quant data, the three most recent Operating Margin figures were 49.0% in Q2 2026, 46.12% in Q1 2026, and 41.33% in Q4 2025.